Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

NCT05411679 is registered in ClinicalTrials.gov with Ellipses Pharma as lead sponsor.

NCT NCT05411679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Lead sponsor
Ellipses Pharma
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2023
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, small-cell lung cancer